India's Cipla has been aggressive about taking aim at Western meds it thinks are too expensive for the Indian market, sometimes targeting those that have seen their patents pushed aside by compulsory licenses. But drugmaker Merck has a new deal with Cipla that might help it sidestep that issue.
written on 20.03.2014
Merck to have Cipla make cut-rate version of an HIV drug
